Trials in Kidney Disease — Time to EVOLVE

Perkovic, V; Neal, B

Access status:

Open Access

Field	Value	Language
dc.contributor.author	Perkovic, V
dc.contributor.author	Neal, B
dc.date.accessioned	2019-12-18
dc.date.available	2019-12-18
dc.date.issued	2012-12-27
dc.identifier.citation	Perkovic V, Neal B. Trials in Kidney Disease — Time to EVOLVE. New England Journal of Medicine. 2012;367(26):2541-2542. doi:10.1056/nejme1212368	en
dc.identifier.uri	https://hdl.handle.net/2123/21544
dc.description.abstract	Patients with kidney disease face a substantially increased risk of cardiovascular events and death — one in five patients who are undergoing dialysis die each year in the United States. Elevated parathyroid hormone levels are almost universal in persons with advanced kidney failure and have been associated with these risks. Cinacalcet is an oral calcimimetic agent approved by the Food and Drug Administration (FDA) in 2004 for the treatment of secondary hyperparathyroidism in patients with dialysis-dependent kidney failure. Early reports supported the possibility that cinacalcet conferred cardiovascular protection and reduced fracture risk, although the statistical power of these studies . . .	en
dc.language.iso	en_AU	en
dc.publisher	Massachusetts Medical Society	en
dc.relation	NHMRC GNT0571281, NHMRC GNT1003111	en
dc.rights	Other	en
dc.title	Trials in Kidney Disease — Time to EVOLVE	en
dc.type	Article	en
dc.identifier.doi	10.1056/NEJMe1212368
dc.type.pubtype	Publisher's version	en
dc.rights.other	From The New England Journal of Medicine, V Perkovic, B Neal, Trials in Kidney Disease — Time to EVOLVE, 367(26):2541-2542. Copyright © (2019) Massachusetts Medical Society. Reprinted with permission.	en
usyd.faculty	Faculty of Medicine and Health, Sydney Medical School	en